Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer

Trial Profile

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
  • Indications Neuroendocrine carcinoma; Prostate cancer
  • Focus First in man; Therapeutic Use
  • Sponsors BioXcel Therapeutics
  • Most Recent Events

    • 14 Nov 2019 According to BioXcel Therapeutics media release, safety and tolerability data from the first patient cohort was presented at the Annual Prostate Cancer Foundation Scientific Retreat.
    • 24 Oct 2019 According to BioXcel Therapeutics media release, a second patient cohort is enrolling and the company expects to report on these additional safety findings by end of year before advancing to the Phase 2 stage of the trial.
    • 24 Oct 2019 According to BioXcel Therapeutics media release, data from the first patient cohort will be presented during the 26th Annual Prostate Cancer Foundation Scientific Retreat that is being held from October 23 - 26, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top